Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 5
1961 1
1962 5
1963 2
1964 2
1966 1
1967 4
1968 2
1969 1
1970 1
1972 1
1973 1
1976 1
1979 1
1982 3
1983 8
1984 9
1985 2
1986 6
1987 5
1988 4
1989 7
1990 8
1991 2
1992 6
1993 7
1994 4
1995 6
1996 4
1997 8
1998 2
1999 2
2000 5
2001 4
2002 1
2003 2
2004 2
2005 1
2006 2
2007 3
2008 1
2009 3
2010 7
2011 3
2012 5
2013 3
2014 3
2015 2
2016 2
2017 3
2018 2
2019 6
2020 5
2021 2
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

181 results
Results by year
Filters applied: . Clear all
Page 1
Exposure-response analysis of Raltitrexed assessing liver toxicity.
Royer B, Schmitt A, Nguyen T, Paillard MJ, Jary M, Demarchi M, Vernerey D, Henriques J, Jacquin M, Borg C, Kim S. Royer B, et al. Among authors: jacquin m. Br J Clin Pharmacol. 2021 Mar;87(3):1327-1337. doi: 10.1111/bcp.14519. Epub 2020 Sep 4. Br J Clin Pharmacol. 2021. PMID: 32789966 Free article. Clinical Trial.
Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma.
Nardin C, Laheurte C, Puzenat E, Boullerot L, Ramseyer M, Marguier A, Jacquin M, Godet Y, Aubin F, Adotevi O. Nardin C, et al. Among authors: jacquin m. J Invest Dermatol. 2022 Feb;142(2):435-444. doi: 10.1016/j.jid.2021.07.160. Epub 2021 Aug 2. J Invest Dermatol. 2022. PMID: 34352265
Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer.
Laheurte C, Thiery-Vuillemin A, Calcagno F, Legros A, Simonin H, Boullerot L, Jacquin M, Nguyen T, Mouillet G, Borg C, Adotévi O. Laheurte C, et al. Among authors: jacquin m. Int J Cancer. 2020 Aug 15;147(4):1199-1205. doi: 10.1002/ijc.32803. Epub 2019 Dec 11. Int J Cancer. 2020. PMID: 31749145 Free article.
GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-κB-Dependent Mechanism.
Mondragón L, Mhaidly R, De Donatis GM, Tosolini M, Dao P, Martin AR, Pons C, Chiche J, Jacquin M, Imbert V, Proïcs E, Boyer L, Doye A, Luciano F, Neels JG, Coutant F, Fabien N, Sormani L, Rubio-Patiño C, Bossowski JP, Muller F, Marchetti S, Villa E, Peyron JF, Gaulard P, Lemonnier F, Asnafi V, Genestier L, Benhida R, Fournié JJ, Passeron T, Ricci JE, Verhoeyen E. Mondragón L, et al. Among authors: jacquin m. Cancer Cell. 2019 Sep 16;36(3):268-287.e10. doi: 10.1016/j.ccell.2019.07.008. Epub 2019 Aug 22. Cancer Cell. 2019. PMID: 31447347 Free article.
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.
Kim S, Meurisse A, Spehner L, Stouvenot M, François E, Buecher B, André T, Samalin E, Jary M, Nguyen T, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, de la Fouchardiere C, Boulbair F, Lakkis Z, Klajer E, Jacquin M, Taieb J, Vendrely V, Vernerey D, Borg C. Kim S, et al. Among authors: jacquin m. Ther Adv Med Oncol. 2020 Dec 4;12:1758835920975356. doi: 10.1177/1758835920975356. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33329760 Free PMC article.
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Kim S, Buecher B, André T, Jary M, Bidard FC, Ghiringhelli F, François É, Taieb J, Smith D, de la Fouchardière C, Desramé J, Samalin E, Parzy A, Baba-Hamed N, Bouché O, Tougeron D, Dahan L, El Hajbi F, Jacquin M, Rebucci-Peixoto M, Spehner L, Vendrely V, Vernerey D, Borg C. Kim S, et al. Among authors: jacquin m. BMC Cancer. 2020 Apr 25;20(1):352. doi: 10.1186/s12885-020-06841-1. BMC Cancer. 2020. PMID: 32334548 Free PMC article. Clinical Trial.
181 results